Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of cisplatin + pemetrexed given before or after stereotactic radiotherapy in stage IB non-small-cell lung cancer
NL-OMON32798Phase 1Not yet recruiting
- Sponsor
- Vrije University Medical Center
- Start
- Dec 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of cisplatin and pemetrexed in non-small cell lung cancer (NSCLC) and bronchial carcinoma (2 arms), sponsored by Vrije University Medical Center. Primary endpoint: Safety and feasibility of cisplatin-pemetrexed before or after stereotactic radiotherapy. Planned start Dec 2008; status: not yet recruiting.
02
Drugs
cisplatinpemetrexed
03
Conditions
non-small cell lung cancer (NSCLC)bronchial carcinoma
Beyond the preview
Go deeper on NL-OMON32798.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON32798.